Crohn's Disease: The Complete Guide to Medical Management

Gary R. Lichtenstein, MD, FACP, FACG, AGAF

Chapter 19: Novel Biological Therapies for Crohn’s Disease (continued)

Iris Dotan, MD; Daniel Rachmilewitz, MD

The most effective biologic therapy that is currently known and approved for commercial use is Remicade (infliximab), the chimeric monoclonal antibody targeting tumor necrosis factor alpha (TNFα) with a remission induction rate of 50% to 60% in active CD1 and response rate of 50% in fistulizing CD.2,3 This is the most effective treatment for active moderate to severe CD and shows promise also in maintenance of remission.4,5 The patient subpopulation that does not respond to this treatment, as well as the patients who lose response or develop side effects, requires an alternative…